Trial Profile
Therapeutic and Biological Effects of Imatinib Mesylate (STI571) in Primary Hypereosinophilic Syndrome (HES), Chronic Eosinophilic Leukemia (CEL) and Chronic Idiopathic Hypereosinophilia (CIH): a Study From the Northern Italy Leukemia Group (NILG).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2011
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Hypereosinophilic syndrome; Leukaemia
- Focus Therapeutic Use
- 27 Nov 2008 New trial record.